The concept of PD-L1/TGFβ dual inhibition was to simultaneously target a receptor (PD-L1) and TGFβ to block tumour-cell-intrinsic and -extrinsic immunosuppressive pathways, respectively. The gene discussed is CD274; the disease is neoplasm.